RECURRENT VULVOVAGINAL CANDIDIASIS IN PERIMENOPAUSAL WOMEN
N.V. Zarochentseva, L.K. Jijihia
For quotation:
Zarochentseva N.V., Dzhidzhikhia L.K. Recurrent vulvovaginal candidiasis in women
in perimenopause. Questions of practical colposcopy. Genital infections. 2023; (1): 38–45.
DOI 10.46393/27826392_2023_1_38
Annotation:
Introduction. Approximately 70–75% of women have experienced vulvovaginal candidiasis (VVC) at least once in their lives. The diagnosis of VVC should be based on clinical symptoms and microscopic detection of pseudohyphae. In recurrent or complicated cases, diagnosis should include cultivation of the fungus with identification of the species. For chronic recurrent VVC (RVVC), maintenance therapy is carried out with oral and local azole drugs. It is relevant to analyze the etiology and pathogenesis, clinical manifestations of VVC and RVVC, the treatment approaches used, as well as our own experience in using the azole drug fenticonazole (Lomexin) in the treatment of RVVC during perimenopause.
Purpose of the study: to evaluate the effectiveness and safety of the azole drug fenticonazole (Lomexin) in a combination of two forms - vaginal suppositories (1000 mg) and 2% cream - in women with RVVC during perimenopause against the background of concomitant menopausal hormonal therapy.
Material and methods. The study included 45 patients with RVVC who were in perimenopause. Clinical examination included complaints at the time of initial admission, medical history and life history; Previous diseases and concomitant pathologies were taken into account. An objective examination of the patients included examination of the external genitalia, examination of the cervix and vagina in the speculum, and collection of clinical material for laboratory testing. Treatment and observation were carried out during the first three days, then after one and three months.
The information material includes data from scientific articles on this topic available in the PubMed database and the scientific electronic library eLibrary.ru, published in recent years.
Results. The majority of women (43 out of 45 patients) indicated rapid relief of symptoms, satisfaction with treatment results exceeded 95.6%. The therapy was well tolerated by patients, without side effects, with a pronounced clinical effect during the first day. There was a significant decrease in the intensity of all symptoms (itching, burning, hyperemia, swelling and infiltration of the skin and mucous membranes) on the second or third day of treatment. Positive results of therapy lasted for six months. It should be noted that treatment with two forms of the drug was well tolerated: general and local side effects when using 2% fenticonazole cream and vaginal suppositories (Lomexin) were not recorded in any of the cases.
Conclusion. Therapeutic efficacy one and three months after treatment was 88.9% (40 patients out of 45 women). The results obtained confirm the existing information about the high effectiveness and safety of fenticonazole (Lomexin) in two forms in the treatment of RVVC in the majority of perimenopausal patients.
Journal “Issues of practical colposcopy. Genital infections" No. 1_2023
https://drive.google.com/file/d/137JZhJmdppROCPcjVUYpIBpS7lp-6CyZ/view
N.V. Zarochentseva, L.K. Jijihia
For quotation:
Zarochentseva N.V., Dzhidzhikhia L.K. Recurrent vulvovaginal candidiasis in women
in perimenopause. Questions of practical colposcopy. Genital infections. 2023; (1): 38–45.
DOI 10.46393/27826392_2023_1_38
Annotation:
Introduction. Approximately 70–75% of women have experienced vulvovaginal candidiasis (VVC) at least once in their lives. The diagnosis of VVC should be based on clinical symptoms and microscopic detection of pseudohyphae. In recurrent or complicated cases, diagnosis should include cultivation of the fungus with identification of the species. For chronic recurrent VVC (RVVC), maintenance therapy is carried out with oral and local azole drugs. It is relevant to analyze the etiology and pathogenesis, clinical manifestations of VVC and RVVC, the treatment approaches used, as well as our own experience in using the azole drug fenticonazole (Lomexin) in the treatment of RVVC during perimenopause.
Purpose of the study: to evaluate the effectiveness and safety of the azole drug fenticonazole (Lomexin) in a combination of two forms - vaginal suppositories (1000 mg) and 2% cream - in women with RVVC during perimenopause against the background of concomitant menopausal hormonal therapy.
Material and methods. The study included 45 patients with RVVC who were in perimenopause. Clinical examination included complaints at the time of initial admission, medical history and life history; Previous diseases and concomitant pathologies were taken into account. An objective examination of the patients included examination of the external genitalia, examination of the cervix and vagina in the speculum, and collection of clinical material for laboratory testing. Treatment and observation were carried out during the first three days, then after one and three months.
The information material includes data from scientific articles on this topic available in the PubMed database and the scientific electronic library eLibrary.ru, published in recent years.
Results. The majority of women (43 out of 45 patients) indicated rapid relief of symptoms, satisfaction with treatment results exceeded 95.6%. The therapy was well tolerated by patients, without side effects, with a pronounced clinical effect during the first day. There was a significant decrease in the intensity of all symptoms (itching, burning, hyperemia, swelling and infiltration of the skin and mucous membranes) on the second or third day of treatment. Positive results of therapy lasted for six months. It should be noted that treatment with two forms of the drug was well tolerated: general and local side effects when using 2% fenticonazole cream and vaginal suppositories (Lomexin) were not recorded in any of the cases.
Conclusion. Therapeutic efficacy one and three months after treatment was 88.9% (40 patients out of 45 women). The results obtained confirm the existing information about the high effectiveness and safety of fenticonazole (Lomexin) in two forms in the treatment of RVVC in the majority of perimenopausal patients.
Journal “Issues of practical colposcopy. Genital infections" No. 1_2023
https://drive.google.com/file/d/137JZhJmdppROCPcjVUYpIBpS7lp-6CyZ/view
